FDA
-
-
-
-
-
-
-
FDA accepts AbbVie's Botox Cosmetic application for jaw slimming use
-
-
-
-
-
-
-
Genmab and AbbVie say epcoritamab trial missed U.S. survival goal
-
-
-
-
-
-
-
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
-
-
-
-
-
-
-
The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It
-
-
-
-
-
-
-
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
-
-
-
-
-
-
-
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
-
-
-
-
-
-
-
AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.
-
330,063 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

